25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

UCB SA
Buy, Hold or Sell?

Let's analyze Ucb together

I guess you are interested in UCB SA. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of UCB SA. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about UCB SA

I send you an email if I find something interesting about UCB SA.

Quick analysis of Ucb (30 sec.)










What can you expect buying and holding a share of Ucb? (30 sec.)

How much money do you get?

How much money do you get?
‚ā¨5.60
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
‚ā¨45.98
Expected worth in 1 year
‚ā¨43.82
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
‚ā¨3.00
Return On Investment
2.0%

For what price can you sell your share?

Current Price per Share
‚ā¨146.55
Expected price per share
‚ā¨125.50 - ‚ā¨146.80
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

1. Valuation of Ucb (5 min.)




Live pricePrice per Share (EOD)

‚ā¨146.55

Intrinsic Value Per Share

‚ā¨-3.62 - ‚ā¨36.56

Total Value Per Share

‚ā¨42.37 - ‚ā¨82.54

2. Growth of Ucb (5 min.)




Is Ucb growing?

Current yearPrevious yearGrowGrow %
How rich?$9.7b$9.8b-$96.5m-1.0%

How much money is Ucb making?

Current yearPrevious yearGrowGrow %
Making money$371.9m$453.2m-$81.3m-21.9%
Net Profit Margin6.5%7.6%--

How much money comes from the company's main activities?

3. Financial Health of Ucb (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#9 / 982

Most Revenue
#3 / 982

Most Profit
#7 / 982

Most Efficient
#129 / 982
3rd party ad coffee SUPPORTERis ad-free.

What can you expect buying and holding a share of Ucb? (5 min.)

Welcome investor! Ucb's management wants to use your money to grow the business. In return you get a share of Ucb.

What can you expect buying and holding a share of Ucb?

First you should know what it really means to hold a share of Ucb. And how you can make/lose money.

Speculation

The Price per Share of Ucb is ‚ā¨146.55. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Ucb.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Ucb, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ‚ā¨45.98. Based on the TTM, the Book Value Change Per Share is ‚ā¨-0.54 per quarter. Based on the YOY, the Book Value Change Per Share is ‚ā¨3.33 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ‚ā¨1.29 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Ucb.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share
Usd Eps1.911.3%1.911.3%2.331.6%3.752.6%3.482.4%
Usd Book Value Change Per Share-0.59-0.4%-0.59-0.4%3.622.5%2.821.9%2.521.7%
Usd Dividend Per Share1.401.0%1.401.0%1.370.9%1.350.9%1.310.9%
Usd Total Gains Per Share0.810.6%0.810.6%4.993.4%4.172.8%3.832.6%
Usd Price Per Share85.56-85.56-79.77-88.53-81.66-
Price to Earnings Ratio44.90-44.90-34.29-27.40-32.32-
Price-to-Total Gains Ratio105.17-105.17-15.98-39.70-32.83-
Price to Book Ratio1.72-1.72-1.58-1.96-2.16-
Price-to-Total Gains Ratio105.17-105.17-15.98-39.70-32.83-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share158.91882
Number of shares6
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share1.401.35
Usd Book Value Change Per Share-0.592.82
Usd Total Gains Per Share0.814.17
Gains per Quarter (6 shares)4.8825.02
Gains per Year (6 shares)19.53100.08
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
134-1410326890
267-283065136190
3101-425097203290
4134-5670129271390
5168-7090162339490
6202-84110194407590
7235-99130226474690
8269-113150258542790
9302-127170291610890
10336-141190323678990

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%22.00.02.091.7%
Book Value Change Per Share0.01.00.00.0%2.01.00.066.7%4.01.00.080.0%8.02.00.080.0%18.06.00.075.0%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%24.00.00.0100.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%20.04.00.083.3%
3rd party ad coffee SUPPORTERis ad-free.

Fundamentals of Ucb

About UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Fundamental data was last updated by Penke on 2024-07-08 00:25:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is overpriced.
3rd party ad coffee SUPPORTERis ad-free.

1.1. Profitability of UCB SA.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit¬†Ucb earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare¬†Ucb to the¬†Biotechnology industry mean.
  • A Net Profit Margin of 6.5%¬†means that¬†€0.07 for each €1¬†in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of UCB SA:

  • The MRQ is 6.5%. The company is making a profit. +1
  • The TTM is 6.5%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ6.5%TTM6.5%0.0%
TTM6.5%YOY7.6%-1.0%
TTM6.5%5Y12.4%-5.9%
5Y12.4%10Y11.9%+0.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.5%-168.6%+175.1%
TTM6.5%-209.9%+216.4%
YOY7.6%-235.1%+242.7%
5Y12.4%-390.8%+403.2%
10Y11.9%-505.1%+517.0%
1.1.2. Return on Assets

Shows how efficient Ucb is using its assets to generate profit.

  • Above 5% is considered healthy¬†but always compare¬†Ucb to the¬†Biotechnology industry mean.
  • 2.2% Return on Assets means that¬†Ucb generated¬†€0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of UCB SA:

  • The MRQ is 2.2%. Using its assets, the company is less efficient in making profit.
  • The TTM is 2.2%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ2.2%TTM2.2%0.0%
TTM2.2%YOY2.6%-0.4%
TTM2.2%5Y5.0%-2.8%
5Y5.0%10Y4.9%+0.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.2%-11.7%+13.9%
TTM2.2%-11.8%+14.0%
YOY2.6%-11.2%+13.8%
5Y5.0%-13.2%+18.2%
10Y4.9%-14.6%+19.5%
1.1.3. Return on Equity

Shows how efficient Ucb is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare¬†Ucb to the¬†Biotechnology industry mean.
  • 3.8% Return on Equity means Ucb generated €0.04¬†for each¬†€1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of UCB SA:

  • The MRQ is 3.8%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 3.8%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ3.8%TTM3.8%0.0%
TTM3.8%YOY4.6%-0.8%
TTM3.8%5Y8.5%-4.7%
5Y8.5%10Y8.4%+0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.8%-14.0%+17.8%
TTM3.8%-15.2%+19.0%
YOY4.6%-14.0%+18.6%
5Y8.5%-18.8%+27.3%
10Y8.4%-19.3%+27.7%
3rd party ad coffee SUPPORTERis ad-free.

1.2. Operating Efficiency of UCB SA.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Ucb is operating .

  • Measures how much profit Ucb makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare¬†Ucb to the¬†Biotechnology industry mean.
  • An Operating Margin of 5.3%¬†means the company generated €0.05 ¬†for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of UCB SA:

  • The MRQ is 5.3%. The company is operating less efficient.
  • The TTM is 5.3%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ5.3%TTM5.3%0.0%
TTM5.3%YOY7.3%-1.9%
TTM5.3%5Y14.6%-9.2%
5Y14.6%10Y16.6%-2.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.3%-351.1%+356.4%
TTM5.3%-224.3%+229.6%
YOY7.3%-243.1%+250.4%
5Y14.6%-396.3%+410.9%
10Y16.6%-510.1%+526.7%
1.2.2. Operating Ratio

Measures how efficient Ucb is keeping operating costs low.

  • Below 1 is considered healthy (always compare to¬†Biotechnology industry mean).
  • An Operation Ratio of 0.95 means that the operating costs are €0.95 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of UCB SA:

  • The MRQ is 0.947. The company is less efficient in keeping operating costs low.
  • The TTM is 0.947. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.947TTM0.9470.000
TTM0.947YOY0.927+0.019
TTM0.9475Y0.854+0.092
5Y0.85410Y0.842+0.012
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9473.004-2.057
TTM0.9473.255-2.308
YOY0.9273.484-2.557
5Y0.8545.004-4.150
10Y0.8426.533-5.691
3rd party ad coffee SUPPORTERis ad-free.

1.3. Liquidity of UCB SA.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Ucb is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to¬†Biotechnology industry mean).
  • A Current Ratio of 1.32¬†means the company has €1.32 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of UCB SA:

  • The MRQ is 1.317. The company is just able to pay all its short-term debts.
  • The TTM is 1.317. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.317TTM1.3170.000
TTM1.317YOY1.062+0.255
TTM1.3175Y1.268+0.048
5Y1.26810Y1.194+0.075
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3173.793-2.476
TTM1.3174.052-2.735
YOY1.0624.945-3.883
5Y1.2685.990-4.722
10Y1.1946.326-5.132
1.3.2. Quick Ratio

Measures if Ucb is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but¬†always compare¬†Ucb to the¬†Biotechnology industry mean.
  • A Quick Ratio of 0.85¬†means the company can pay off €0.85 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of UCB SA:

  • The MRQ is 0.847. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.847. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.847TTM0.8470.000
TTM0.847YOY0.717+0.130
TTM0.8475Y0.978-0.131
5Y0.97810Y0.827+0.151
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8473.186-2.339
TTM0.8473.581-2.734
YOY0.7174.803-4.086
5Y0.9785.922-4.944
10Y0.8276.430-5.603
3rd party ad coffee SUPPORTERis ad-free.

1.4. Solvency of UCB SA.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Ucb assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare¬†Ucb to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.42¬†means that Ucb assets are¬†financed with 42.2% credit (debt) and the remaining percentage (100% - 42.2%)¬†is financed by its owners/shareholders.¬†

Let's take a look of the Debt to Asset Ratio trends of UCB SA:

  • The MRQ is 0.422. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.422. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.422TTM0.4220.000
TTM0.422YOY0.429-0.006
TTM0.4225Y0.417+0.006
5Y0.41710Y0.438-0.022
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4220.330+0.092
TTM0.4220.340+0.082
YOY0.4290.287+0.142
5Y0.4170.368+0.049
10Y0.4380.383+0.055
1.4.2. Debt to Equity Ratio

Measures if Ucb is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but¬†always compare¬†Ucb to the¬†Biotechnology industry mean.
  • A Debt to Equity ratio of 73.1% means that company has €0.73 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of UCB SA:

  • The MRQ is 0.731. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.731. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.731TTM0.7310.000
TTM0.731YOY0.751-0.019
TTM0.7315Y0.717+0.014
5Y0.71710Y0.783-0.066
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7310.366+0.365
TTM0.7310.415+0.316
YOY0.7510.369+0.382
5Y0.7170.441+0.276
10Y0.7830.483+0.300
3rd party ad coffee SUPPORTERis ad-free.

2. Market Valuation of UCB SA

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures¬†how much money you pay¬†for each share for¬†every €1 in earnings Ucb generates.

  • Above 15 is considered overpriced but¬†always compare¬†Ucb to the¬†Biotechnology industry mean.
  • A PE ratio of 44.90 means the investor is paying €44.90¬†for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of UCB SA:

  • The EOD is 83.397. Based on the earnings, the company is expensive. -2
  • The MRQ is 44.899. Based on the earnings, the company is overpriced. -1
  • The TTM is 44.899. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD83.397MRQ44.899+38.497
MRQ44.899TTM44.8990.000
TTM44.899YOY34.287+10.612
TTM44.8995Y27.402+17.497
5Y27.40210Y32.316-4.914
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD83.397-2.610+86.007
MRQ44.899-3.020+47.919
TTM44.899-2.891+47.790
YOY34.287-3.549+37.836
5Y27.402-6.222+33.624
10Y32.316-6.322+38.638
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of UCB SA:

  • The EOD is 95.034. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The MRQ is 51.164. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The TTM is 51.164. Based on how much money comes from the company's main activities, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD95.034MRQ51.164+43.869
MRQ51.164TTM51.1640.000
TTM51.164YOY19.160+32.004
TTM51.1645Y26.802+24.363
5Y26.80210Y31.610-4.809
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD95.034-3.139+98.173
MRQ51.164-3.748+54.912
TTM51.164-3.717+54.881
YOY19.160-5.038+24.198
5Y26.802-7.998+34.800
10Y31.610-8.522+40.132
3rd party ad coffee SUPPORTERis ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Ucb is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy¬†(always compare to Biotechnology industry mean).
  • A PB ratio of 1.72 means the investor is paying €1.72¬†for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of UCB SA:

  • The EOD is 3.187. Based on the equity, the company is fair priced.
  • The MRQ is 1.716. Based on the equity, the company is underpriced. +1
  • The TTM is 1.716. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD3.187MRQ1.716+1.471
MRQ1.716TTM1.7160.000
TTM1.716YOY1.581+0.135
TTM1.7165Y1.959-0.243
5Y1.95910Y2.160-0.201
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.1871.928+1.259
MRQ1.7162.247-0.531
TTM1.7162.301-0.585
YOY1.5812.387-0.806
5Y1.9593.674-1.715
10Y2.1604.139-1.979
2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

3. Summary

3.1. Key Performance Indicators

The key performance indicators of UCB SA compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.541-0.5410%3.334-116%2.604-121%2.320-123%
Book Value Per Share--45.98145.9810%46.522-1%42.012+9%35.665+29%
Current Ratio--1.3171.3170%1.062+24%1.268+4%1.194+10%
Debt To Asset Ratio--0.4220.4220%0.429-1%0.417+1%0.438-4%
Debt To Equity Ratio--0.7310.7310%0.751-3%0.717+2%0.783-7%
Dividend Per Share--1.2911.2910%1.268+2%1.241+4%1.207+7%
Eps--1.7571.7570%2.145-18%3.459-49%3.206-45%
Free Cash Flow Per Share--1.5421.5420%3.839-60%3.541-56%3.236-52%
Free Cash Flow To Equity Per Share--0.7020.7020%4.198-83%2.867-76%1.212-42%
Gross Profit Margin---3.647-3.6470%-2.562-30%-1.510-59%-1.700-53%
Intrinsic Value_10Y_max--36.556--------
Intrinsic Value_10Y_min---3.615--------
Intrinsic Value_1Y_max--3.632--------
Intrinsic Value_1Y_min--2.352--------
Intrinsic Value_3Y_max--10.937--------
Intrinsic Value_3Y_min--4.759--------
Intrinsic Value_5Y_max--18.270--------
Intrinsic Value_5Y_min--4.616--------
Market Cap27811818177.600+45%15400491000.00015400491000.0000%14331989040.000+7%15816629664.560-3%14475680982.568+6%
Net Profit Margin--0.0650.0650%0.076-14%0.124-48%0.119-45%
Operating Margin--0.0530.0530%0.073-27%0.146-63%0.166-68%
Operating Ratio--0.9470.9470%0.927+2%0.854+11%0.842+12%
Pb Ratio3.187+46%1.7161.7160%1.581+9%1.959-12%2.160-21%
Pe Ratio83.397+46%44.89944.8990%34.287+31%27.402+64%32.316+39%
Price Per Share146.550+46%78.90078.9000%73.560+7%81.638-3%75.301+5%
Price To Free Cash Flow Ratio95.034+46%51.16451.1640%19.160+167%26.802+91%31.610+62%
Price To Total Gains Ratio195.339+46%105.167105.1670%15.984+558%39.700+165%32.833+220%
Quick Ratio--0.8470.8470%0.717+18%0.978-13%0.827+2%
Return On Assets--0.0220.0220%0.026-16%0.050-56%0.049-55%
Return On Equity--0.0380.0380%0.046-17%0.085-55%0.084-55%
Total Gains Per Share--0.7500.7500%4.602-84%3.845-80%3.527-79%
Usd Book Value--9732490000.0009732490000.0000%9829001600.000-1%8828317280.000+10%7440068400.000+31%
Usd Book Value Change Per Share---0.586-0.5860%3.616-116%2.824-121%2.516-123%
Usd Book Value Per Share--49.86249.8620%50.448-1%45.558+9%38.675+29%
Usd Dividend Per Share--1.4001.4000%1.375+2%1.346+4%1.309+7%
Usd Eps--1.9061.9060%2.326-18%3.751-49%3.477-45%
Usd Free Cash Flow--326404400.000326404400.0000%811131200.000-60%743681520.000-56%673737720.000-52%
Usd Free Cash Flow Per Share--1.6721.6720%4.163-60%3.840-56%3.509-52%
Usd Free Cash Flow To Equity Per Share--0.7610.7610%4.553-83%3.109-76%1.314-42%
Usd Market Cap30159135631.789+45%16700292440.40016700292440.4000%15541608914.976+7%17151553208.249-3%15697428457.497+6%
Usd Price Per Share158.919+46%85.55985.5590%79.768+7%88.528-3%81.656+5%
Usd Profit--371949200.000371949200.0000%453279200.000-18%725029840.000-49%628409800.000-41%
Usd Revenue--5695268800.0005695268800.0000%5982634800.000-5%5813685280.000-2%5126934760.000+11%
Usd Total Gains Per Share--0.8140.8140%4.990-84%4.170-80%3.825-79%
 EOD+4 -4MRQTTM+0 -0YOY+10 -265Y+9 -2710Y+15 -21

3.2. Fundamental Score

Let's check the fundamental score of UCB SA based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1583.397
Price to Book Ratio (EOD)Between0-13.187
Net Profit Margin (MRQ)Greater than00.065
Operating Margin (MRQ)Greater than00.053
Quick Ratio (MRQ)Greater than10.847
Current Ratio (MRQ)Greater than11.317
Debt to Asset Ratio (MRQ)Less than10.422
Debt to Equity Ratio (MRQ)Less than10.731
Return on Equity (MRQ)Greater than0.150.038
Return on Assets (MRQ)Greater than0.050.022
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of UCB SA based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5065.522
Ma 20Greater thanMa 50142.153
Ma 50Greater thanMa 100135.722
Ma 100Greater thanMa 200125.862
OpenGreater thanClose144.850
Total4/5 (80.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-12-312020-12-312021-12-312022-12-312023-12-31
Long-term Assets Other  -5,047,00095,000-4,952,000-205,000-5,157,000-143,000-5,300,0005,341,00041,000



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets15,539,000
Total Liabilities6,564,000
Total Stockholder Equity8,975,000
 As reported
Total Liabilities 6,564,000
Total Stockholder Equity+ 8,975,000
Total Assets = 15,539,000

Assets

Total Assets15,539,000
Total Current Assets3,444,000
Long-term Assets12,095,000
Total Current Assets
Cash And Cash Equivalents 861,000
Short-term Investments 108,000
Net Receivables 1,140,000
Inventory 1,031,000
Other Current Assets 304,000
Total Current Assets  (as reported)3,444,000
Total Current Assets  (calculated)3,444,000
+/-0
Long-term Assets
Property Plant Equipment 1,595,000
Goodwill 5,254,000
Intangible Assets 4,232,000
Long-term Assets Other 41,000
Long-term Assets  (as reported)12,095,000
Long-term Assets  (calculated)11,122,000
+/- 973,000

Liabilities & Shareholders' Equity

Total Current Liabilities2,616,000
Long-term Liabilities3,948,000
Total Stockholder Equity8,975,000
Total Current Liabilities
Short-term Debt 42,000
Short Long Term Debt 1,000
Accounts payable 537,000
Other Current Liabilities 1,833,000
Total Current Liabilities  (as reported)2,616,000
Total Current Liabilities  (calculated)2,413,000
+/- 203,000
Long-term Liabilities
Long term Debt 2,878,000
Capital Lease Obligations 161,000
Long-term Liabilities  (as reported)3,948,000
Long-term Liabilities  (calculated)3,039,000
+/- 909,000
Total Stockholder Equity
Common Stock584,000
Retained Earnings 6,578,000
Accumulated Other Comprehensive Income 136,000
Other Stockholders Equity 1,677,000
Total Stockholder Equity (as reported)8,975,000
Total Stockholder Equity (calculated)8,975,000
+/-0
Other
Capital Stock584,000
Cash and Short Term Investments 969,000
Common Stock Shares Outstanding 195,190
Current Deferred Revenue204,000
Liabilities and Stockholders Equity 15,539,000
Net Debt 2,177,000
Net Invested Capital 11,852,000
Net Working Capital 828,000
Property Plant and Equipment Gross 2,983,000
Short Long Term Debt Total 3,038,000



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-312002-12-312001-12-312000-12-31
> Total Assets 
2,303,136
2,563,854
2,620,935
3,090,935
5,373,540
4,717,000
10,498,000
9,555,000
9,524,000
9,120,000
8,969,000
9,178,000
9,360,000
9,760,000
10,148,000
10,956,000
10,212,000
9,917,000
10,514,000
11,081,000
13,319,000
14,210,000
15,868,000
15,539,000
15,539,00015,868,00014,210,00013,319,00011,081,00010,514,0009,917,00010,212,00010,956,00010,148,0009,760,0009,360,0009,178,0008,969,0009,120,0009,524,0009,555,00010,498,0004,717,0005,373,5403,090,9352,620,9352,563,8542,303,136
   > Total Current Assets 
0
0
1,731,644
1,789,831
1,911,978
1,303,000
2,355,000
1,655,000
1,837,000
1,794,000
1,731,000
1,706,000
1,822,000
2,424,000
2,501,000
2,838,000
2,331,000
2,677,000
2,950,000
3,295,000
3,582,000
3,710,000
3,304,000
3,444,000
3,444,0003,304,0003,710,0003,582,0003,295,0002,950,0002,677,0002,331,0002,838,0002,501,0002,424,0001,822,0001,706,0001,731,0001,794,0001,837,0001,655,0002,355,0001,303,0001,911,9781,789,8311,731,64400
       Cash And Cash Equivalents 
109,031
88,782
482,376
449,199
148,369
424,000
974,000
479,000
463,000
486,000
494,000
267,000
318,000
750,000
507,000
1,285,000
761,000
1,049,000
1,262,000
329,000
662,000
1,263,000
899,000
861,000
861,000899,0001,263,000662,000329,0001,262,0001,049,000761,0001,285,000507,000750,000318,000267,000494,000486,000463,000479,000974,000424,000148,369449,199482,37688,782109,031
       Short-term Investments 
266,929
339,054
420,732
359,051
400,359
0
0
96,000
3,000
53,000
61,000
38,000
8,000
1,000
1,000
34,000
46,000
14,000
17,000
989,000
704,000
110,000
170,000
108,000
108,000170,000110,000704,000989,00017,00014,00046,00034,0001,0001,0008,00038,00061,00053,0003,00096,00000400,359359,051420,732339,054266,929
       Net Receivables 
741,773
822,046
438,545
903,218
847,109
567,000
891,000
741,000
870,000
806,000
690,000
832,000
813,000
795,000
529,000
586,000
659,000
591,000
632,000
880,000
939,000
1,134,000
993,000
1,140,000
1,140,000993,0001,134,000939,000880,000632,000591,000659,000586,000529,000795,000813,000832,000690,000806,000870,000741,000891,000567,000847,109903,218438,545822,046741,773
       Other Current Assets 
44,898
27,990
37,287
33,468
539,442
51,000
58,000
773,000
141,000
850,000
742,000
864,000
880,000
252,000
917,000
401,000
333,000
426,000
392,000
317,000
423,000
325,000
335,000
304,000
304,000335,000325,000423,000317,000392,000426,000333,000401,000917,000252,000880,000864,000742,000850,000141,000773,00058,00051,000539,44233,46837,28727,99044,898
   > Long-term Assets 
0
0
889,291
1,301,104
3,461,562
3,414,000
8,143,000
7,900,000
7,687,000
7,326,000
7,238,000
7,472,000
7,538,000
6,771,000
6,855,000
6,965,000
6,827,000
6,469,000
6,761,000
7,786,000
9,737,000
10,500,000
12,564,000
12,095,000
12,095,00012,564,00010,500,0009,737,0007,786,0006,761,0006,469,0006,827,0006,965,0006,855,0006,771,0007,538,0007,472,0007,238,0007,326,0007,687,0007,900,0008,143,0003,414,0003,461,5621,301,104889,29100
       Property Plant Equipment 
495,978
580,258
589,413
726,458
699,906
500,000
666,000
758,000
623,000
534,000
505,000
500,000
602,000
722,000
686,000
651,000
678,000
673,000
805,000
840,000
1,035,000
1,275,000
1,434,000
1,595,000
1,595,0001,434,0001,275,0001,035,000840,000805,000673,000678,000651,000686,000722,000602,000500,000505,000534,000623,000758,000666,000500,000699,906726,458589,413580,258495,978
       Goodwill 
22,387
51,184
43,922
221,759
2,266,446
1,663,000
4,346,000
4,403,000
4,579,000
4,552,000
4,718,000
4,799,000
4,823,000
4,694,000
4,882,000
5,164,000
5,178,000
4,838,000
4,970,000
5,059,000
4,964,000
5,173,000
5,340,000
5,254,000
5,254,0005,340,0005,173,0004,964,0005,059,0004,970,0004,838,0005,178,0005,164,0004,882,0004,694,0004,823,0004,799,0004,718,0004,552,0004,579,0004,403,0004,346,0001,663,0002,266,446221,75943,92251,18422,387
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
79,000
92,000
113,000
103,000
166,000
127,000
140,000
0
0
0
0
0000140,000127,000166,000103,000113,00092,00079,0000000000000000
       Intangible Assets 
96,750
96,566
254,829
462,960
595,071
721,000
2,537,000
2,293,000
2,169,000
1,953,000
1,641,000
1,525,000
1,483,000
1,336,000
1,242,000
1,078,000
898,000
840,000
893,000
5,898,000
7,937,000
8,332,000
10,156,000
4,232,000
4,232,00010,156,0008,332,0007,937,0005,898,000893,000840,000898,0001,078,0001,242,0001,336,0001,483,0001,525,0001,641,0001,953,0002,169,0002,293,0002,537,000721,000595,071462,960254,82996,56696,750
       Long-term Assets Other 
0
0
634,462
111,686
2,166,585
354,000
484,000
106,000
155,000
65,000
79,000
63,000
48,000
-498,000
-682,000
-843,000
-953,000
-715,000
-760,000
-5,047,000
-4,952,000
-5,157,000
-5,300,000
41,000
41,000-5,300,000-5,157,000-4,952,000-5,047,000-760,000-715,000-953,000-843,000-682,000-498,00048,00063,00079,00065,000155,000106,000484,000354,0002,166,585111,686634,46200
> Total Liabilities 
1,097,362
1,173,637
1,055,655
1,307,166
3,408,586
2,308,000
5,720,000
5,291,000
5,507,000
4,703,000
4,377,000
4,355,000
4,767,000
5,437,000
5,258,000
5,410,000
4,735,000
4,181,000
4,259,000
4,072,000
6,047,000
5,824,000
6,804,000
6,564,000
6,564,0006,804,0005,824,0006,047,0004,072,0004,259,0004,181,0004,735,0005,410,0005,258,0005,437,0004,767,0004,355,0004,377,0004,703,0005,507,0005,291,0005,720,0002,308,0003,408,5861,307,1661,055,6551,173,6371,097,362
   > Total Current Liabilities 
718,016
724,931
854,097
744,129
2,791,317
707,000
1,521,000
1,886,000
2,554,000
2,062,000
1,853,000
1,612,000
1,808,000
2,345,000
2,605,000
3,061,000
2,418,000
1,949,000
2,152,000
2,394,000
2,814,000
2,824,000
3,112,000
2,616,000
2,616,0003,112,0002,824,0002,814,0002,394,0002,152,0001,949,0002,418,0003,061,0002,605,0002,345,0001,808,0001,612,0001,853,0002,062,0002,554,0001,886,0001,521,000707,0002,791,317744,129854,097724,931718,016
       Short-term Debt 
0
0
0
98,354
1,970,716
31,000
65,000
514,000
917,000
566,000
308,000
45,000
197,000
723,000
373,000
623,000
27,000
39,000
149,000
306,000
431,000
55,000
262,000
42,000
42,000262,00055,000431,000306,000149,00039,00027,000623,000373,000723,000197,00045,000308,000566,000917,000514,00065,00031,0001,970,71698,354000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
2,750,000
194,000
707,000
25,000
37,000
111,000
268,000
396,000
17,000
222,000
1,000
1,000222,00017,000396,000268,000111,00037,00025,000707,000194,0002,750,0000000000000000
       Accounts payable 
253,057
234,467
210,345
305,345
397,544
525,000
1,142,000
1,108,000
1,159,000
1,036,000
1,172,000
1,294,000
261,000
297,000
312,000
342,000
409,000
402,000
481,000
403,000
513,000
596,000
573,000
537,000
537,000573,000596,000513,000403,000481,000402,000409,000342,000312,000297,000261,0001,294,0001,172,0001,036,0001,159,0001,108,0001,142,000525,000397,544305,345210,345234,467253,057
       Other Current Liabilities 
293,130
327,426
854,097
75,965
79,107
151,000
314,000
264,000
129,000
63,000
79,000
116,000
1,350,000
2,048,000
2,293,000
1,907,000
1,876,000
1,435,000
1,459,000
1,547,000
1,662,000
1,850,000
2,026,000
1,833,000
1,833,0002,026,0001,850,0001,662,0001,547,0001,459,0001,435,0001,876,0001,907,0002,293,0002,048,0001,350,000116,00079,00063,000129,000264,000314,000151,00079,10775,965854,097327,426293,130
   > Long-term Liabilities 
0
0
201,558
563,037
617,269
1,601,000
4,199,000
3,405,000
2,953,000
2,641,000
2,524,000
2,743,000
2,959,000
2,015,000
1,738,000
1,650,000
1,591,000
1,531,000
1,287,000
1,678,000
3,233,000
3,000,000
3,692,000
3,948,000
3,948,0003,692,0003,000,0003,233,0001,678,0001,287,0001,531,0001,591,0001,650,0001,738,0002,015,0002,959,0002,743,0002,524,0002,641,0002,953,0003,405,0004,199,0001,601,000617,269563,037201,55800
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,585,000
1,574,000
1,534,000
1,350,000
975,000
0
0
0
0
0000975,0001,350,0001,534,0001,574,0001,585,000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
-98,354
-1,970,716
-31,000
-65,000
-514,000
-917,000
-566,000
-308,000
-45,000
-197,000
-723,000
-373,000
-623,000
-20,000
-34,000
-48,000
-207,000
-321,000
80,000
-122,000
119,000
119,000-122,00080,000-321,000-207,000-48,000-34,000-20,000-623,000-373,000-723,000-197,000-45,000-308,000-566,000-917,000-514,000-65,000-31,000-1,970,716-98,354000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
33,000
0
0
0
0
1,000
0
0
001,000000033,0000000000000000000
> Total Stockholder Equity
1,188,843
1,382,174
1,545,030
1,783,769
1,954,466
2,409,000
4,574,000
4,263,000
4,013,000
4,415,000
4,590,000
4,821,000
4,594,000
4,454,000
5,002,000
5,672,000
5,584,000
5,813,000
6,310,000
7,039,000
7,271,000
8,386,000
9,064,000
8,975,000
8,975,0009,064,0008,386,0007,271,0007,039,0006,310,0005,813,0005,584,0005,672,0005,002,0004,454,0004,594,0004,821,0004,590,0004,415,0004,013,0004,263,0004,574,0002,409,0001,954,4661,783,7691,545,0301,382,1741,188,843
   Common Stock
437,799
437,799
437,799
437,799
437,799
438,000
2,148,000
2,151,000
2,151,000
2,151,000
550,000
2,151,000
2,151,000
550,000
584,000
584,000
584,000
584,000
584,000
584,000
584,000
584,000
584,000
584,000
584,000584,000584,000584,000584,000584,000584,000584,000584,000584,000550,0002,151,0002,151,000550,0002,151,0002,151,0002,151,0002,148,000438,000437,799437,799437,799437,799437,799
   Retained Earnings Total Equity000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
-42,000
46,000
703,000
-10,000
-255,000
-356,000
-162,000
-413,000
-127,000
368,000
136,000
136,000368,000-127,000-413,000-162,000-356,000-255,000-10,000703,00046,000-42,0000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,030,000
2,030,000
2,030,000
2,030,000
2,030,000
0
0
0
0
00002,030,0002,030,0002,030,0002,030,0002,030,000000000000000000
   Treasury Stock0000-377,000-342,000-357,000-283,000-295,000-173,000-168,000-239,000-262,000-125,000-125,000-125,000-127,000-124,000-95,00000000
   Other Stockholders Equity 
0
0
1,107,231
1,345,970
1,516,667
-169,000
39,000
-281,000
-414,000
-366,000
4,590,000
56,000
-226,000
1,437,000
1,857,000
1,470,000
1,737,000
1,418,000
1,332,000
1,653,000
1,637,000
1,635,000
1,667,000
1,677,000
1,677,0001,667,0001,635,0001,637,0001,653,0001,332,0001,418,0001,737,0001,470,0001,857,0001,437,000-226,00056,0004,590,000-366,000-414,000-281,00039,000-169,0001,516,6671,345,9701,107,23100



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.